Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02906631
Other study ID # AOR 15096
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 27, 2017
Est. completion date December 1, 2023

Study information

Verified date March 2024
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Introduction: Acute encephalitis (AE) is a severe neurological disorder associated with significant morbidity and mortality. Approximately 50% of patients with AE require ICU admission because of coma, seizures or acute respiratory failure. Determinants of neurological prognosis in these patients are not known. Objectives: Main objective: To identify determinants of outcome in adult patients admitted to the ICU; Secondary objectives: a) To study the impact of diagnostic studies (Brain MRI, CSF analysis, EEG) on neurologic outcome; b) to describe the epidemiology of patients admitted to the ICU with AE; c) to study the impact of early appropriate therapy on neurologic outcomes; d) to describe morbidity and mortality associated with AE at 90 days and 1 year following diagnosis. Methods: prospective observational multicenter study in French ICUs. All patients admitted to the ICU for probable or confirmed AE (2013 IDSA criteria)with a Glasgow coma scale score < or =to 13 will be eligible for inclusion. Factors associated with a poor prognosis at 90 days will be identified by multivariable logistic regression analysis. Duration of study: 30 months (recruitment 18 months, follow-up 12 months). Patients: 300 patients Endpoints: - Primary endpoint: The primary endpoint is the modified Rankin scale score 90 days following onset of abnormal status (GCS < or =13). This score will be determined by contacting the patient. A poor outcome will be defined as a mRS >2 at 90 days. - Secondary endpoints: a) neurological findings within 7 days following onset of altered mental status; b) abnormal findings on diagnostic studies (MRI, EEG, CSF analysis) within7 days following onset of altered mental status; c) Time between onset of altered mental status and completion of diagnostic studies; d)Time between onset of altered mental status and start of appropriate specific therapy; e) neurologic outcomes at 1 year mRS score and extended Glasgow outcome scale (GOS); f) causes of death in non-survivors at 1 year; g) quality of life and posttraumatic stress at 1 year: IADL and SF36 scales;


Description:

Acute encephalitis (AE) is a serious condition associated with significant morbidity and mortality. Patients require ICU admission in 60 % of cases, mainly because of neurological symptoms (coma, seizures) or acute respiratory failure. The etiological profile of AE has changed considerably in recent years, with the emergence of new pathogens and the description of new immune-mediated causes (acute disseminated encephalomyelitis (ADEM), autoimmune limbic encephalitis) that require urgent specific therapies. Furthermore, despite extensive investigations, the proportion of cases of unknown cause remains high. In-ICU care of patients with AE is a difficult task, given the diversity of etiologies and clinical presentations. Furthermore, additional studies such as magnetic resonance imaging (MRI) can be challenging to obtain in this population. Finally, there are no specific recommendations on the management and prognostic assessment of patients admitted to the ICU with AE. Present available data on the prognosis of patients with AE include both adult and pediatric cases, and focuses only on AE with identified causes. Prognosis of encephalitis in adult patients requiring ICU admission has been previously described only in retrospective single centre cohorts. To date, no prospective multicenter study on AE has been conducted in the specific population of adult critically ill patients. Furthermore, data on the diagnostic and prognostic contributions of magnetic resonance imaging (MRI) and electroencephalography studies in these patients are lacking The development of guidelines for standardized care in critically ill AE patients is needed, and will include management of early life support, prompt and exhaustive etiologic investigations, early administration of specific treatments and assessment of neurological prognosis. This study, which will focus on prognostic evaluation of severe AE in adults, appears crucial to support the development of such guidelines. Patients admitted to ICU for a suspicion of AE (acute encephalopathy and CSF pleocytosis > 5 cells / microliter) will be eligible for inclusion. Patients admitted to ICU for a suspicion of AE (acute encephalopathy and CSF pleocytosis > 5 cells / microliter) will be eligible for inclusion. Eligible patients will be included if they fulfil the IDSA 2013 diagnostic criteria for ""probable"" or ""confirmed"" encephalitis (see inclusion criteria). In patients without an obvious etiological diagnosis, an algorithm will be suggested to investigators to guide etiological investigations, according to the most recent recommendations (IDSA 2013). Aetiology of encephalitis will be described according to a priori-defined categories: 1) viral causes, 2) immune-mediated-causes, 3) bacterial or fungal meningitis with secondary encephalitic features, 4) undetermined causes. For each included patient, CSF and plasma samples will be stored at -80°C. A biobank will be created for subsequent analyses (etiological diagnosis, prognostic biomarkers). Outcomes will be assessed at 90 days and 365 days by contacting the patient or his relatives. The primary outcome is the score on the modified Rankin scale, which will be assessed 90 days after inclusion. Independent predictors of functional outcomes will be determined by multivariate logistic regression analysis.


Recruitment information / eligibility

Status Completed
Enrollment 350
Est. completion date December 1, 2023
Est. primary completion date April 20, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Altered mental status, delirium, or personality changes for a duration > or = 24 h - At least 2 of the following: 1) fever (>38°C) within 72 hours before or following hospital admission; 2) new-onset seizures; 3) new-onset focal signs; 4) CSF pleocytosis > 5 cell / microl; 5) brain parenchyma abnormalities on neuroimaging compatible with the diagnosis of encephalitis; 6) EEG abnormalities compatible with the diagnosis of encephalitis. - Altered mental status with a GCS < or =13 without sedation, or GCS < or =13 before sedation administration in sedated patients - CSF analysis performed - Brain imaging performed (CT/MRI) - Age >18 Exclusion criteria: - Time between the first hospitalization for neurologic symptoms in relation with encephalitis and ICU admission > 21 days - Purulent bacterial meningitis diagnosed by direct examination or CSF analysis - Isolated brain abscess. - Febrile encephalopathy associated with another diagnosis - Predicted time in ICU < or = 24 hours - Opposition of close-of-kin, if present at the inclusion, for patient participation in research.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Hôpital Bichat-Claude Bernard Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Neurological status on the modified Rankin scale The primary outcome measure is the modified Rankin scale score 90 days following onset of abnormal status (defined by a GCS score< or =13). This score will be determined by contacting the patient or his relatives. A poor outcome will be defined as a mRS >2 at 90 days. 90 days
Secondary Biological data within 7 days following onset of altered mental status 7 days
Secondary State of consciousness defined by the Glasgow Coma Scale within 7 days following onset of altered mental status 7 days
Secondary Patient's comorbidity measured by Charlson Comorbidity Index 7 days
Secondary Presence of focal neurological deficit within 7 days following onset of altered mental status 7 days
Secondary Presence of thermal dysregulation within 7 days following onset of altered mental status 7 days
Secondary Presence of seizures within 7 days following onset of altered mental status 7 days
Secondary Magnetic resonance imaging anomalies within 7 days following onset of altered mental status 7 days
Secondary Electrophysiologic anomalies within 7 days following onset of altered mental status 7 days
Secondary Time between onset of altered mental status and cerebrospinal fluid analysis one year
Secondary Time between onset of altered mental status and brain magnetic resonance imaging study one year
Secondary Time between onset of altered mental status and electroencephalogram study one year
Secondary Time between onset of altered mental status and completion of diagnostic studies (CSF analysis, MRI, EEG) one year
Secondary Number of patients with primitive acute encephalitis (AE) Number of patients with infectious causes leading to primitive AE 7 days
Secondary Number of patients with infectious causes leading to meningitis with secondary encephalitic features 7 days
Secondary Number of patients with immune-mediated causes of encephalitis 7 days
Secondary Number of patients with other infectious causes of encephalitis 7 days
Secondary Proportion of patients with appropriate specific therapy 7 days
Secondary Time between onset of altered mental status and appropriate specific therapy one year
Secondary Neurological status on the modified Rankin scale This score will be determined by contacting the patient or his relatives. 365 days
Secondary Hospital anxiety and depression scale (HAD) 365 days
Secondary Quality of life measured by SF36 scale 365 days
Secondary INSTRUMENTAL ACTIVITIES OF DAILY LIVING SCALE (IADL) 365 days
Secondary Neurological prognosis on the extended Glasgow outcome scale 365 days
See also
  Status Clinical Trial Phase
Completed NCT02538094 - tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis N/A
Completed NCT00381433 - Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid Phase 1
Completed NCT00031486 - Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir Phase 3
Completed NCT00069303 - Natural History of West Nile Virus Infection N/A
Completed NCT02367664 - A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants Phase 3
Completed NCT00314132 - Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. Phase 3
Terminated NCT00927953 - Treatment of West Nile Virus With MGAWN1 Phase 2
Recruiting NCT05393492 - Regulating Emotions and Behaviors After Brain Injury N/A
Terminated NCT04361344 - Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection N/A
Recruiting NCT04460599 - Neurological Features During COVID19
Recruiting NCT04372615 - The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis Phase 2
Completed NCT02714959 - IL-2 in Refractory Autoimmune Encephalitis Phase 1/Phase 2
Completed NCT01092507 - A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers Phase 3
Completed NCT01041573 - Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population Phase 3
Not yet recruiting NCT04722328 - Establishment of Prevention and Control System of Central Nervous System Infection
Recruiting NCT06067750 - Comparison of Narcotrend and Cerebral Function Analysing Monitor in Intensive Care to Monitor Seizures and Deep Sedation
Not yet recruiting NCT06368648 - CoMind Early Feasibility Study
Completed NCT02526550 - Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX Phase 4
Completed NCT01694524 - Nervous System Infections Among Patients With Febrile Seizure N/A
Completed NCT04080921 - Stem Cell Transplantation In-patient With Neurological Sequelae Due to Encephalitis or Meningitis Phase 1/Phase 2